



## Clinical trial results: Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)

### Summary

EudraCT number	2016-001964-13
Trial protocol	Outside EU/EEA
Global end of trial date	03 November 2015

### Results information

Result version number	v1 (current)
This version publication date	20 October 2017
First version publication date	20 October 2017

### Trial information

#### Trial identification

Sponsor protocol code	HAF85
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01838070
WHO universal trial number (UTN)	U1111-1127-7211

Notes:

### Sponsors

Sponsor organisation name	Sanofi Pasteur Korea Ltd
Sponsor organisation address	11 fl, 235, Banpo-daero, Seocho-gu Seoul, Korea, Republic of, 137-804
Public contact	Global Medical Affairs Rep., Sanofi Pasteur Korea Ltd, 82 22136 9533, RegistryContactUS@sanofipasteur.com
Scientific contact	Global Medical Affairs Rep., Sanofi Pasteur Korea Ltd, 82 22136 9533, RegistryContactUS@sanofipasteur.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 November 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 November 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety of AVAXIM 160U (Hepatitis A vaccine) administered under the routine practice, according to Korea Food and Drug Administration "Basic standard for reexamination of new drug" based on the pharmaceutical law in Korea.

Protection of trial subjects:

No vaccination was administered during this trial. Subjects in this trial previously received AVAXIM 160U (Hepatitis A vaccine) and safety events occurring within 30 days after vaccination under the routine practice during the 4-year surveillance period is reported here.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	04 November 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 614
Worldwide total number of subjects	614
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	14
Adults (18-64 years)	596
From 65 to 84 years	4

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Study subjects were enrolled for a 4-year surveillance period (04 November 2011 to 03 November 2015) at 16 clinic centers in South Korea.

### Pre-assignment

Screening details:

A total of 614 subjects whose case report forms were retrieved were included in the safety evaluation.

### Period 1

Period 1 title	4-year surveillance period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not applicable

### Arms

Arm title	All subjects
-----------	--------------

Arm description:

Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved.

Arm type	Experimental
Investigational medicinal product name	Avaxim® 160U Injection (Hepatitis A Vaccine)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL, intramuscular, single injection on Day 0.

<b>Number of subjects in period 1</b>	All subjects
Started	614
Completed	614

## Baseline characteristics

### Reporting groups

Reporting group title	All subjects
-----------------------	--------------

Reporting group description:

Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved.

Reporting group values	All subjects	Total	
Number of subjects	614	614	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	14	14	
Adults (18-64 years)	596	596	
From 65-84 years	4	4	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	32.19		
standard deviation	± 8.25	-	
Gender categorical			
Units: Subjects			
Female	386	386	
Male	228	228	

## End points

### End points reporting groups

Reporting group title	All subjects
Reporting group description:	
Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved.	

### Primary: Number of Subjects Reporting Solicited Injection-Site and Systemic Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine)

End point title	Number of Subjects Reporting Solicited Injection-Site and Systemic Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine) <sup>[1]</sup>
-----------------	---

End point description:

1. Solicited injection site reaction (Pain and Erythema) occurring during 7 days after the AVAXIM 160U administration during the 4-year surveillance period. Grade 3: Pain, Significant, prevents daily activity and Erythema, >100 mm.
2. Solicited systemic adverse reactions (Fever [Temperature], Headache, Myalgia or Arthralgia, Asthenia and Gastro-intestinal disorders) occurring during 7 days after the AVAXIM 160U administration during the 4-year surveillance period. Grade 3: Fever,  $\geq 39.0^{\circ}\text{C}$ ; Headache, Myalgia, Arthralgia, Asthenia, and Gastro-intestinal disorders, Significant, prevents daily activity.

End point type	Primary
----------------	---------

End point timeframe:

7 days after the AVAXIM 160U administration during the 4-year surveillance period.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study group and the study vaccine previously administered for this outcome.

End point values	All subjects			
Subject group type	Reporting group			
Number of subjects analysed	614			
Units: Number of subjects				
number (not applicable)				
Any Injection site Pain	9			
Grade 3 Injection site Pain	0			
Any Injection site Erythema	3			
Grade 3 Injection site Erythema	0			
Any Fever	3			
Grade 3 Fever	0			
Any Headache	4			
Grade 3 Headache	0			
Any Myalgia	2			
Grade 3 Myalgia	0			
Any Arthralgia	0			
Grade 3 Arthralgia	0			
Any Asthenia	0			
Grade 3 Asthenia	0			
Any Gastro-intestinal disorders	1			
Grade 3 Gastro-intestinal disorders	0			

## Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Number of Subjects Reporting Unexpected Adverse Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine)

End point title	Number of Subjects Reporting Unexpected Adverse Events Following A Single Dose of Avaxim 160U Injection (Hepatitis A Vaccine)
-----------------	---

End point description:

The number subjects with unsolicited adverse events following a single dose of Avaxim 160 U Injection (Hepatitis A Vaccine) are reported.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

30 days after the AVAXIM 160U administration during the 4-year surveillance period.

End point values	All subjects			
Subject group type	Reporting group			
Number of subjects analysed	614			
Units: Number of subjects				
number (not applicable)				
Bronchitis	4			
Pharyngitis	4			
Nasopharyngitis	3			
Influenza	1			
Laryngitis	1			
Vaginal infection	1			
Vulvovaginal candidiasis	1			
Stomatitis	1			
Vomiting	1			
Chest pain	1			
Inflammation	1			
Cough	2			
Conjunctival disorder	1			
Back pain	1			
Dizziness	1			
Ectropion of cervix	1			
Uterine cervical erosion	1			
Vulvovaginal pruritus	1			
Dermatitis contact	1			

## **Statistical analyses**

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected throughout the 4-year surveillance period.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

### Reporting groups

Reporting group title	All subjects
-----------------------	--------------

Reporting group description:

Subjects who were 16 to 84 years old who previously received Avaxim 160U for 16 years old and older (Hepatitis A vaccine) injection once, were enrolled during the 4-year surveillance period, and whose Case Report forms were retrieved.

Serious adverse events	All subjects		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 614 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0.1 %

Non-serious adverse events	All subjects		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 614 (2.28%)		
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 614 (0.16%)		
occurrences (all)	1		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 614 (0.16%)		
occurrences (all)	1		
Inflammation			
subjects affected / exposed	1 / 614 (0.16%)		
occurrences (all)	1		

<p>Eye disorders</p> <p>Conjunctival disorder</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 614 (0.16%)</p> <p>1</p>		
<p>Gastrointestinal disorders</p> <p>Dyspepsia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Gastrointestinal inflammation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 614 (0.33%)</p> <p>2</p> <p>1 / 614 (0.16%)</p> <p>1</p> <p>1 / 614 (0.16%)</p> <p>1</p> <p>1 / 614 (0.16%)</p> <p>1</p>		
<p>Reproductive system and breast disorders</p> <p>Ectropion of cervix</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Uterine cervical erosion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vulvovaginal pruritus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 614 (0.16%)</p> <p>1</p> <p>1 / 614 (0.16%)</p> <p>1</p> <p>1 / 614 (0.16%)</p> <p>1</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 614 (0.33%)</p> <p>2</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>Dermatitis contact</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 614 (0.16%)</p> <p>1</p>		
<p>Musculoskeletal and connective tissue disorders</p>			

Back pain subjects affected / exposed occurrences (all)	1 / 614 (0.16%) 1		
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	4 / 614 (0.65%) 4		
Pharyngitis subjects affected / exposed occurrences (all)	4 / 614 (0.65%) 4		
Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 614 (0.49%) 3		
Influenza subjects affected / exposed occurrences (all)	1 / 614 (0.16%) 1		
Laryngitis subjects affected / exposed occurrences (all)	1 / 614 (0.16%) 1		
Vaginal infection subjects affected / exposed occurrences (all)	1 / 614 (0.16%) 1		
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	1 / 614 (0.16%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 August 2013	Updated inclusion criteria, methods of recruitment, and informed consent forms.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported